Hikal Ltd Upgraded to Hold by MarketsMOJO Amid Mixed Financial and Technical Signals

Technical Trends Shift to Mildly Bullish

The primary catalyst for the rating upgrade stems from a positive shift in Hikal’s technical outlook. The technical trend has moved from a sideways pattern to a mildly bullish stance, supported by several key indicators. On a weekly basis, the Moving Average Convergence Divergence (MACD) is bullish, while the monthly MACD remains bearish, indicating short-term momentum improvement but longer-term caution.

The Relative Strength Index (RSI) presents a mixed picture: no clear signal weekly but bullish monthly, suggesting growing strength over the medium term. Bollinger Bands show mild bullishness weekly but mild bearishness monthly, reinforcing the notion of short-term gains tempered by longer-term volatility.

Moving averages on a daily scale remain mildly bearish, reflecting recent price softness. However, the Know Sure Thing (KST) oscillator is bullish weekly but bearish monthly, and Dow Theory assessments are mildly bullish on both weekly and monthly timeframes. On-Balance Volume (OBV) readings are bullish across weekly and monthly charts, indicating positive volume trends supporting price moves.

Despite a day change of -2.26% on 20 July 2026, the technical indicators collectively suggest a cautious but improving momentum, justifying the upgrade from a technical perspective.

Valuation Remains Attractive Despite Profit Declines

Hikal’s valuation metrics continue to favour a Hold rating. The company trades at ₹228.95 per share, down from a previous close of ₹234.25, with a 52-week high of ₹355.00 and a low of ₹145.95. Its Enterprise Value to Capital Employed ratio stands at a modest 1.9, indicating an attractive valuation relative to capital utilisation.

Return on Capital Employed (ROCE) is reported at 3%, which, while modest, supports the valuation argument. Compared to peers in the Pharmaceuticals & Biotechnology sector, Hikal is trading at a discount to historical averages, offering potential value for investors willing to weather volatility.

However, the stock’s returns have been disappointing over the last year, with a -34.83% decline versus a -4.99% drop in the Sensex. Over five years, the stock has fallen -55.86%, significantly underperforming the Sensex’s 47.07% gain. This underperformance tempers enthusiasm and justifies a Hold rather than a Buy rating.

Financial Trends Show Mixed Signals

Recent quarterly results for Q4 FY25-26 have been encouraging, with Profit Before Tax Less Other Income (PBT LESS OI) surging to ₹48.80 crores, representing a remarkable 1345.9% growth compared to the previous four-quarter average. Operating profit to interest coverage ratio has reached a high of 7.22 times, signalling improved ability to service debt.

The company’s debt-equity ratio is at a low 0.57 times as of the half-year, reflecting a conservative capital structure. These factors contribute positively to the financial trend assessment and support the upgrade to Hold.

Nevertheless, long-term fundamentals remain weak. Operating profits have declined at a compound annual growth rate (CAGR) of -24.95% over the past five years. The Debt to EBITDA ratio is elevated at 3.10 times, indicating some strain in debt servicing capacity. Return on Equity (ROE) averages 7.60%, reflecting low profitability per unit of shareholder funds.

Profitability has also been under pressure, with a 60% fall in profits over the past year, which is a significant concern for investors seeking sustainable growth.

Institutional Investor Participation Dwindling

Another factor influencing the rating is the declining stake of institutional investors. Over the previous quarter, institutional holdings decreased by -0.73%, now constituting only 8.63% of the company’s share capital. Given that institutional investors typically possess superior analytical resources, their reduced participation may signal caution about the company’s prospects.

This trend, combined with consistent underperformance against the BSE500 benchmark over the last three years, reinforces the Hold rating rather than a more optimistic Buy.

Performance Relative to Sensex and Sector Benchmarks

Hikal’s stock returns have been volatile and generally disappointing relative to the broader market. Over the past week, the stock declined by -6.46% while the Sensex gained 0.75%. However, over the last month, Hikal outperformed with a 20.44% gain compared to Sensex’s 1.29% rise, indicating some short-term recovery.

Year-to-date returns are marginally positive at 0.90%, outperforming the Sensex’s -8.30%. Yet, over one, three, and five-year periods, the stock has underperformed significantly, with returns of -34.83%, -24.14%, and -55.86% respectively, compared to Sensex gains of -4.99%, 17.36%, and 47.07% over the same periods.

Over a decade, Hikal has delivered a cumulative return of 100.13%, which, while positive, lags the Sensex’s 180.75% gain, underscoring the company’s challenges in generating sustained shareholder value.

Summary of Ratings and Scores

MarketsMOJO currently assigns Hikal Ltd a Mojo Score of 50.0, reflecting a Hold rating, upgraded from a previous Sell grade. The company is classified as a small-cap within the Pharmaceuticals & Biotechnology sector. The upgrade was officially recorded on 17 July 2026, with the latest market data dated 20 July 2026.

This rating reflects a balanced view: improved technical indicators and recent financial performance are offset by weak long-term fundamentals, declining institutional interest, and persistent underperformance against benchmarks.

Outlook for Investors

Investors considering Hikal Ltd should weigh the recent positive technical momentum and quarterly financial improvements against the company’s longer-term challenges. The attractive valuation metrics and low debt-equity ratio provide some cushion, but the weak profitability trends and institutional selling caution against aggressive accumulation.

Given these factors, a Hold rating is appropriate, signalling that investors may consider maintaining existing positions while monitoring for further fundamental improvements or technical confirmation before increasing exposure.

Conclusion

Hikal Ltd’s upgrade to Hold from Sell is primarily driven by a shift in technical trends towards mild bullishness and a strong quarterly financial performance that contrasts with prior quarters. However, the company’s weak long-term profit growth, low return on equity, and reduced institutional participation temper enthusiasm. The stock’s valuation remains attractive relative to peers, but persistent underperformance against the Sensex and sector benchmarks suggests caution.

Overall, the rating change reflects a cautious optimism, recommending investors to hold their positions while closely watching for sustained improvements in fundamentals and market sentiment.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →